Emi Kurimoto

508 total citations
15 papers, 408 citations indexed

About

Emi Kurimoto is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Cognitive Neuroscience. According to data from OpenAlex, Emi Kurimoto has authored 15 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Cellular and Molecular Neuroscience and 4 papers in Cognitive Neuroscience. Recurrent topics in Emi Kurimoto's work include Receptor Mechanisms and Signaling (10 papers), Neuroscience and Neuropharmacology Research (5 papers) and Neuropeptides and Animal Physiology (4 papers). Emi Kurimoto is often cited by papers focused on Receptor Mechanisms and Signaling (10 papers), Neuroscience and Neuropharmacology Research (5 papers) and Neuropeptides and Animal Physiology (4 papers). Emi Kurimoto collaborates with scholars based in Japan, Israel and United States. Emi Kurimoto's co-authors include Hiroshi Katsuki, Toshiaki Kume, Akinori Akaike, Haruki Shibata, Haruhide Kimura, Yūji Shimizu, Motohisa Suzuki, Yoichiro Isohama, Yasuhiko Izumi and Maiko Tanaka and has published in prestigious journals such as PLoS ONE, Current Biology and Neuroscience.

In The Last Decade

Emi Kurimoto

15 papers receiving 398 citations

Peers

Countries citing papers authored by Emi Kurimoto

Since Specialization

Citations

This map shows the geographic impact of Emi Kurimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emi Kurimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emi Kurimoto more than expected).

Fields of papers citing papers by Emi Kurimoto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emi Kurimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emi Kurimoto. The network helps show where Emi Kurimoto may publish in the future.

Co-authorship network of co-authors of Emi Kurimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Emi Kurimoto. A scholar is included among the top collaborators of Emi Kurimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emi Kurimoto. Emi Kurimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	An orexin agonist promotes wakefulness and inhibits cataplexy through distinct brain regions 2025 ·Current Biology ·Takashi Ishikawa, Emi Kurimoto, (unknown), Tatsuki Koike, Haruhide Kimura, Thomas E. Scammell	3
2	0047 Mapping orexin 2 receptor pathways that improve sleepiness and cataplexy 2023 ·SLEEP ·Takashi Ishikawa, Emi Kurimoto, (unknown), Thomas E. Scammell	1
3	0045 Characterization of a novel narcolepsy mouse model with conditional ablation of the orexin neurons 2023 ·SLEEP ·Emi Kurimoto, Takashi Ishikawa, (unknown), Thomas E. Scammell	1
4	Therapeutic potential of TAK-071, a muscarinic M1 receptor positive allosteric modulator with low cooperativity, for the treatment of cognitive deficits and negative symptoms associated with schizophrenia 2021 ·Neuroscience Letters ·Emi Kurimoto, Ryuji Yamada, Takeshi Hirakawa, Haruhide Kimura	7
5	T‐495, a novel low cooperative M₁ receptor positive allosteric modulator, improves memory deficits associated with cholinergic dysfunction and is characterized by low gastrointestinal side effect risk 2020 ·Pharmacology Research & Perspectives ·(unknown), (unknown), Emi Kurimoto, Yūji Shimizu, Minoru Nakamura, Makoto Fushimi, Ryouta Maeda, Maki Miyamoto, Haruhide Kimura	10
6	TAK-071, a muscarinic M1 receptor positive allosteric modulator, attenuates scopolamine-induced quantitative electroencephalogram power spectral changes in cynomolgus monkeys 2019 ·PLoS ONE ·Emi Kurimoto, Masato Nakashima, Haruhide Kimura, Motohisa Suzuki	16
7	In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents 2019 ·Neuroscience ·(unknown), (unknown), Emi Kurimoto, Maiko Tanaka, Motohisa Suzuki, Atsushi Nakatani, Haruhide Kimura	16
8	TAK-071, a novel M1 positive allosteric modulator with low cooperativity, improves cognitive function in rodents with few cholinergic side effects 2018 ·Neuropsychopharmacology ·(unknown), Emi Kurimoto, (unknown), Atsushi Suzuki, Maiko Tanaka, Motohisa Suzuki, Yūji Shimizu, Masami Yamada, Haruhide Kimura	43
9	FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Keiji Nishiyama, Hirobumi Suzuki, (unknown), Noriko Suzuki, Emi Kurimoto, Takayuki Kawai, Minoru Maruyama, Hidetoshi Komatsu, Kensuke Sakuma, Yūji Shimizu, Masato Shimojo	25
10	An Approach to Discovering Novel Muscarinic M1 Receptor Positive Allosteric Modulators with Potent Cognitive Improvement and Minimized Gastrointestinal Dysfunction 2017 ·Journal of Pharmacology and Experimental Therapeutics ·Emi Kurimoto, Satoru Matsuda, Yūji Shimizu, (unknown), (unknown), Takahiro Sugimoto, Hiroki Sakamoto, Haruhide Kimura	23
11	Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists 2017 ·Bioorganic & Medicinal Chemistry ·(unknown), Y. ITO, Izumi Nomura, (unknown), Yūji Shimizu, Emi Kurimoto, Kazunobu Aoyama, Kazuyoshi Aso	16
12	[P2–048]: AN APPROACH TO DISCOVER NOVEL MUSCARINIC M₁ RECEPTOR‐POSITIVE ALLOSTERIC MODULATORS WITH POTENT COGNITIVE IMPROVEMENT AND MINIMIZED GASTROINTESTINAL DYSFUNCTION 2017 ·Alzheimer s & Dementia ·Emi Kurimoto, Satoru Matsuda, Yūji Shimizu, (unknown), (unknown), Takahiro Sugimoto, Hiroki Sakamoto, Haruhide Kimura	1
13	[P2–051]: IN VITRO CHARACTERIZATION OF TAK‐071: A NOVEL MUSCARINIC M₁ RECEPTOR‐POSITIVE ALLOSTERIC MODULATOR WITH LOW COOPERATIVITY 2017 ·Alzheimer s & Dementia ·Haruhide Kimura, Yūji Shimizu, Atsushi Suzuki, Emi Kurimoto, (unknown), Masami Yamada, (unknown)	2
14	Retinoic acid receptor stimulation protects midbrain dopaminergic neurons from inflammatory degeneration via BDNF‐mediated signaling 2009 ·Journal of Neurochemistry ·Hiroshi Katsuki, Emi Kurimoto, (unknown), Yuki Kurauchi, Akinori Hisatsune, Yoichiro Isohama, Yasuhiko Izumi, Toshiaki Kume, Koichi Shudo, Akinori Akaike	74
15	Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults 2006 ·Biochemical Pharmacology ·(unknown), Hiroshi Katsuki, Emi Kurimoto, Haruki Shibata, Toshiaki Kume, Akinori Akaike	170

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact